← Back to headlines
EyePoint Pharmaceuticals Aims for Mid-2026 Topline Data for DURAVYU in Wet AMD and DME
EyePoint Pharmaceuticals is targeting mid-2026 for topline data release for its drug DURAVYU, currently in Phase III trials for wet AMD and DME.
4 Mar, 22:12 — 4 Mar, 22:12
Sources
Showing 1 of 1 sources
